NCT02434328View on ClinicalTrials.gov

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2

PHASE3CompletedINTERVENTIONAL
Enrollment

1,048

Participants

Timeline

Start Date

July 28, 2015

Primary Completion Date

April 5, 2017

Study Completion Date

March 8, 2018

Conditions
Neovascular Age-Related Macular DegenerationChoroidal Neovascularization
Interventions
DRUG

Brolucizumab ophthalmic solution

Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose

DRUG

Aflibercept ophthalmic solution

Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY